6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
Deep dive into DAPA-HF follow-up and extension data for dapagliflozin in HFrEF, covering durability of benefit, long-term safety, and post-trial outcomes beyond the original 2019 NEJM publication.
Deep-dive into DAPA-HF pre-specified and post-hoc subgroup analyses by age, sex, BMI, diabetes status, race, and baseline biomarkers, revealing which heart failure patients benefit most from dapagliflozin.
A plain-English deep dive into the DAPA-HF trial: the methodology, enrollment criteria, results tables, limitations, and what the 26% reduction in worsening heart failure or CV death means for clinical practice today.
A clinical-research deep dive into the real methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest considerations of the DAPA-HF trial of dapagliflozin in heart failure with reduced ejection fraction.
A deep dive into the DAPA-HF trial design, randomization, blinding, endpoint adjudication, statistical framework, and what each methodological choice means for interpreting the 26% reduction in worsening heart failure or cardiovascular death with dapagliflozin.
A deep-dive into the DAPA-HF trial examining how dapagliflozin reshaped heart failure treatment guidelines, prescribing patterns, and patient selection beyond the original 2019 NEJM publication.